NCT00790140 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Status UNKNOWN Phase PHASE4
NCT00788801 Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain Status COMPLETED Phase PHASE1
NCT00786708 Sensitivity and Specificity of NGAL in an Emergency Room Population Status COMPLETED Phase N/A
NCT00785616 A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence Status COMPLETED Phase PHASE4
NCT00775606 Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease Status TERMINATED Phase PHASE4
NCT00771498 An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Status COMPLETED Phase PHASE4
NCT00768690 A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 Status COMPLETED Phase PHASE1
NCT00761514 Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira Status TERMINATED Phase PHASE4
NCT00754104 Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors Status WITHDRAWN Phase PHASE1
NCT00752856 Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients Status COMPLETED Phase PHASE2
NCT00752687 A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults Status COMPLETED Phase PHASE1
NCT00752037 Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients Status COMPLETED Phase PHASE4
NCT00747318 A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005 Status COMPLETED Phase PHASE3
NCT00743470 A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects Status TERMINATED Phase PHASE1
NCT00743028 Assess the Oral Bioavailability of New ABT-263 Formulations Status COMPLETED Phase PHASE1